Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 3/20 | 0.40 |
| ▸ | JAK2 | O60674 | 2/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | WNT1 | P04628 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 3/20 | 0.34 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10091083 | 0.92 | CNR2 (0.39) | CNR2JAK2NTRK1CHRM3LMNA | |
| SCHEMBL4119853 | 0.86 | CNR2 (0.55) | CNR2JAK2NTRK1CHRM3LMNA | |
| SCHEMBL4126162 | 0.86 | CNR2 (0.55) | CNR2JAK2NTRK1CHRM3LMNA | |
| SCHEMBL4119856 | 0.86 | CNR2 (0.55) | CNR2JAK2NTRK1CHRM3LMNA | |
| SCHEMBL342663 | 0.85 | CNR2 (0.57) | CNR2 | |
| SCHEMBL342662 | 0.85 | CNR2 (0.57) | CNR2 | |
| SCHEMBL10091015 | 0.85 | CNR2 (0.57) | CNR2 | |
| SCHEMBL13292817 | 0.85 | CNR2 (0.43) | CNR2CHRM3LMNAWNT1DYRK1A | |
| SCHEMBL13292819 | 0.85 | CNR2 (0.43) | CNR2CHRM3LMNAWNT1DYRK1A | |
| SCHEMBL10091028 | 0.85 | CNR2 (0.47) | CNR2CHRM3LMNAWNT1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835422-B2 | Substituted imidazoheterocycle derivatives | CARA THERAPEUTICS, INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-8835422-B2 | Substituted imidazoheterocycle derivatives | CARA THERAPEUTICS, INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-20120015930-A1 | SUBSTITUTED IMIDAZOHETEROCYCLE DERIVATIVES | CARA THERAPEUTICS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120015930-A1 | SUBSTITUTED IMIDAZOHETEROCYCLE DERIVATIVES | CARA THERAPEUTICS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| WO-2010068520-A2 | SUBSTITUTED IMIDAZOHETEROCYCLE DERIVATIVES | CARA THERAPEUTICS, INC. (US) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015930-A1 | SUBSTITUTED IMIDAZOHETEROCYCLE DERIVATIVES | CNR1, CNR2, HRH1 | CNR2 2/4885JAK2 843/4885NTRK1 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.